




Your Weekly Update from Simon de Lusignan, Director of RCGP RSC



Flu Hunters Needed!

We'd like to offer our thanks to all our sampling practices, the Flu Hunters!

Our sample volumes continue to rise which will help UKHSA understand what diseases and viral strains are in the community and in which regions they're spreading most.

About a third of our swabs are coming from London, with a significant portion also provided by practices in the South East region. We'd love to get more from right across the country! So if you're a practice in East England or the South West, come join the fight and help us meet our **1000 samples a week** target!

Contact our PLO Team at: practiceenquiries@phc.ox.ac.uk We'll help answer any questions and provide the kits to get you set up and swabbing. Thank you!

Payments for Your Samples



We will be sending out our invoice requests a little earlier this month so that your payments can be processed before the upcoming holiday period. If you are a sampling practice, you should expect them by the end of next week.

This will be for all virology swabs and serology samples taken between September 1st to the 30th of November.

Payments for swabs taken from the 1st of September will be paid the new higher rate of **£12.50 per swab**.

ClinT Of The Week

Remember, *coding is caring!* Please code a disease as a problem.



Acute bronchitis (disorder)
SCTID: 10509002

10509002 | Acute bronchitis (disorder) |
Acute bronchitis
Acute bronchitis (disorder)

Publication Of The Week



[The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative - PubMed \(nih.gov\)](#)

Fighting pandemics requires an established infrastructure for pandemic preparedness, with existing, sustainable platforms ready to be activated. This includes platforms for disease surveillance, virus circulation, and vaccine performance monitoring based on Real-World data, to complement clinical trial evidence.

The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project, which established a platform for measuring brand-specific influenza vaccine effectiveness in Europe, exemplifies how to build a collaborative platform with transparent governance, state-of-the-art methodology, and a large network of participating sites.

The DRIVE partners propose that a debate on the benefits of Public-Private-Partnership-

generated real-world evidence for vaccine effectiveness monitoring should be pursued to clarify roles and responsibilities, set up expectations, and decide the future environment for vaccine monitoring in Europe. In parallel, the driving factors behind PPP hesitancy should be studied.

Click the link above to find out more about the areas covered in this exciting European initiative.